Positioning Therapies in the Management of Crohn's Disease

被引：28

作者：

Nguyen, Nghia H. ^{[1
]}

Singh, Siddharth ^{[1
,2
]}

Sandborn, William J. ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA

[2] Univ Calif San Diego, Dept Med, Div Biomed Informat, La Jolla, CA 92093 USA

来源：

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2020年 / 18卷 / 06期

基金：

美国国家卫生研究院;

关键词：

Crohn's; IBD; Therapies; Biologics; Treatment; INFLAMMATORY-BOWEL-DISEASE; PSORIASIS LONGITUDINAL ASSESSMENT; BIOLOGIC-NAIVE PATIENTS; COMBINATION THERAPY; INFLIXIMAB; RISK; ASSOCIATION; AZATHIOPRINE; ADALIMUMAB; SAFETY;

D O I：

10.1016/j.cgh.2019.10.035

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

In the past decade, several new therapies with different mechanisms of action have been approved for the management of moderate to severe Crohn's disease. However, there is limited guidance on optimal positioning of agents as first- or second-line therapies because of the absence of head-to-head trials. Furthermore, given the lack of comparative studies, treatment guidelines have provided limited insight. In this review, we discuss data on key treatment attributes, comparative efficacy and safety, factors predictive of response to each agent, and propose an algorithm for positioning therapies for the management of patients with low-risk and high-risk Crohn's disease.

引用

页码：1268 / 1279

页数：12

共 50 条

[41] Medical Management of Crohn's Disease: Treatment Algorithms 2009
Hanauer, Stephen B.
DIGESTIVE DISEASES, 2009, 27 (04) : 536 - 541
[42] Adalimumab in pediatric Crohn's disease
Patel, Ashish S.
Suarez, Lisbet D.
Rosh, Joel R.
IMMUNOTHERAPY, 2016, 8 (02) : 127 - 133
[43] Drug Therapies and the Risk of Malignancy in Crohn's Disease: Results From the TREAT™ Registry
Lichtenstein, Gary R.
Feagan, Brian G.
Cohen, Russell D.
Salzberg, Bruce A.
Diamond, Robert H.
Langholff, Wayne
Londhe, Anil
Sandborn, William J.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (02) : 212 - 223
[44] Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease
Oh, Eun Hye
Ko, Dae-Hyun
Seo, Hyungil
Chang, Kiju
Kim, Gwang-Un
Song, Eun Mi
Seo, Myeongsook
Lee, Ho-Su
Hwang, Sung Wook
Yang, Dong-Hoon
Ye, Byong Duk
Byeon, Jeong-Sik
Myung, Seung-Jae
Yang, Suk-Kyun
Park, Sang Hyoung
WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (08) : 1489 - 1496
[45] Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Na⟨ve Crohn's Disease
Benmassaoud, Amine
Al-Taweel, Talal
Sasson, Mark Solomon
Moza, Dasha
Strohl, Matthew
Kopylov, Uri
Paradis-Surprenant, Laurence
Almaimani, Mohanad
Bitton, Alain
Afif, Waqqas
Lakatos, Peter L.
Bessissow, Talat
DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (05) : 1302 - 1310
[46] Positioning Therapies in Ulcerative Colitis
Danese, Silvio
Fiorino, Gionata
Peyrin-Biroulet, Laurent
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (06) : 1280 - +
[47] Medical therapies for postoperative Crohn's disease
Shah, Ravi S.
Click, Benjamin H.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
[48] Probiotics and prebiotics in Crohn's disease therapies
Lichtenstein, Lev
Avni-Biron, Irit
Ben-Bassat, Ofer
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2016, 30 (01) : 81 - 88
[49] Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment
Moran, Gordon W.
Dubeau, Marie-France
Kaplan, Gilaad G.
Yang, Hong
Seow, Cynthia H.
Fedorak, Richard N.
Dieleman, Levinus A.
Barkema, Herman W.
Ghosh, Subrata
Panaccione, Remo
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (03) : 434 - +
[50] The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients
Wong, D. R.
Pierik, M.
Seinen, M. L.
van Bodegraven, A. A.
Gilissen, L. P. L.
Bus, P.
Bakker, J. A.
Masclee, A. A. M.
Neef, C.
Engels, L. G. J. B.
Hooymans, P. M.
JOURNAL OF CROHNS & COLITIS, 2014, 8 (02) : 120 - 128

← 1 2 3 4 5 →